Tom Borg discusses ZuriMED and its new FDA-cleared product, FiberLocker, in an interview with SmartTRAK at AANA in Washington, DC.

ZuriMED Technologies’ Tom Borg discusses the company and its recently FDA-cleared product, FiberLocker, in an interview with SmartTRAK at the Arthroscopy Association of North America (AANA) Annual Meeting, held May 8-10, 2025, in Washington, DC. 

To find out more about the company and its novel FiberLocker System, a combination product comprised of SpeedPatch, a synthetic, non-woven polyethylene terephthalate (PET) patch and FiberLocker Instrument, which delivers and fixates the patch onto the repaired tendon, listen to the following video (4:13 min). A link to download a transcript of the interview is also provided below. 

SmartTRAK: Hi. This is Emily Meng with SmartTRAK, and I’m here with Tom from ZuriMED. Hi, Tom.

Tom Borg: Good morning, Emily.

Tom, why don’t you tell us about FiberLock System and how you differentiate it from your competitors.

TB: So, FiberLocker is unique in that it focuses on the mechanical component of what is typically the reason rotator cuff repairs fail. They fail usually at the suture tendon interface. And so there has been a lot of effort over the past 10 to 20 years in trying to augment the integrity of the rotator cuff with biologics and different suturing configurations. But the unfortunate truth is, the quality and consistency of the tendon still remains quite poor and compromised. So ZuriMED, with the help of some very talented engineers and a brilliant surgeon idea, developed a...

Click the button below to download the complete transcript of our interview with Zurimed's Tom Borg at AANA 2025, conducted by SmartTRAK's Emily Meng,

SmartTRAK highlights the key trends in the US Arthroscopic Technologies Market that will drive growth in 2025 and beyond.

The Arthroscopic Technologies (AT) Market is poised for significant advancements as we move through 2025 and beyond. With an anticipated compound annual growth rate (CAGR) of 4.3%, the US AT market is projected to rapidly expand by 2028. This growth is driven by technological innovations and the increasing prevalence of minimally invasive procedures.

In this downloadable market outlook article, SmartTRAK highlights the top technology trends to watch in 2025 that are shaping the future of AT, including:

• Continued Evolution in Arthroscopic Visualization
  • The arthroscopic visualization segment is undergoing a transformation driven by technological advancements and shifting market dynamics, increasing at ... (read more)
• Growth in Bundled Solutions
  • In the AT space, consumables such as resection tools, radiofrequency (RF) devices and fluid management products are significant revenue drivers. SmartTRAK estimates ... (read more)
• ASC Shift Driving Demand for All-in-One Solutions
  • The growth of ASCs has heightened the demand for all-in-one solutions, enabling sports medicine companies to ... (read more)
• Growing Interest in Direct Display Communications
  • SmartTRAK expects to see growing interest in direct display communications in 2025. Building on these advancements in integrated arthroscopic visualization, the next frontier is  ... (read more)
• Challenges and Future Outlook
  • While advancements in arthroscopic technologies are progressing, they remain ... (read more)

Want to stay ahead of the curve in arthroscopic technologies for 2025 and beyond? Click the button below to download Andy Knapik's market outlook article, "The Future of Arthroscopic Technologies in 2025 and Beyond." As SmartTRAK’s Sr Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies, Andy provides an informative analysis of the latest market shifts, including the challenges ahead for the industry.

Dr. Chris Jeffery, founder and CEO of Convergence Medical, discusses the V01, the world's first arthroscopic surgical robot.

In a recent interview with SmartTRAK, Dr. Chris Jeffery, the founder and CEO of Convergence Medical, discussed the V01, the world’s first dedicated arthroscopic surgical robot. In the interview, Dr. Jeffery shared insights into the V01’s novel design, business model, and technological advancements that position it as the next evolution in arthroscopic innovation. The V01 received FDA breakthrough designation in 2023 and is on track for FDA clearance and a US launch in late 2025.

Click on the following video to watch the interview (59:11 min). A complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

Interview Topics By Timecode:

• 00:50 Dr Jeffery’s background.
• 10:00 V01 overview.
• 20:25 Performing a repair with the V01.
• 26:50 V01 cost.
• 36:10 Surgeon feedback.
• 40:10 Importance of an arthroscopy-specific robot.
• 42:40 Novel design of the V01.
• 44:45 Commercial path.

Click the button below to download a complete transcript of SmartTRAK's interview with Dr. Chris Jeffrey, CEO of Convergence Medical Sciences, conducted by Andy Knapik, Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.